The art of targeting cancer therapies: an interview with Professor Paul Workman
This article was originally published in Scrip
Whilst there have been many successes in Professor Paul Workman's 30-year career in cancer drug development, the past year arguably serves as the greatest testament to the quality of his endeavours. In April, Roche, the large pharma company most focused on cancer drug development, announced that it would pay $175 million to acquire Piramed Pharma, the private UK biotechnology company that he along with three others founded in 2003.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.